✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Recovery · Peptide Reference

BPC-157

Released: Last reviewed:

Synthetic peptide derived from a protective protein in human gastric juice. Promotes angiogenesis, tendon-to-bone healing, and gut barrier repair in animal models.

Recovery Evidence grade: C Not FDA-approved
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Key facts

Class
Pentadecapeptide (15 amino acids)
Half-life
~30 min IV; longer effective duration via SC injection
Pharmacy pathway
No recognized 503A bulk pathway (see the FDA status notice)
Sports-ban status
Prohibited by WADA (S0, non-approved substances) since 2022
Common stack
TB-500 (Thymosin Beta-4 fragment)
Common dose
250-500 mcg SC daily for 4-8 weeks
Evidence grade
C (mostly animal data; very limited human data)
FDA status
Not FDA-approved (compounded)

Mechanism of action

Synthetic peptide derived from a protective protein in human gastric juice. Promotes angiogenesis, tendon-to-bone healing, and gut barrier repair in animal models.

Standard dosing

Typical clinical use: 250-500 mcg SC daily for 4-8 weeks. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. BPC-157 requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved (compounded). FDA limits which peptides a pharmacy may compound; check this page’s dated FDA status notice before assuming a peptide is legally available. Ask which licensed pharmacy fills the prescription and check that pharmacy’s license with your state board of pharmacy.

U.S. telehealth providers prescribing BPC-157

The most commonly cited U.S. telehealth providers for BPC-157 are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD —, whose offerings for this peptide we have not verified (see the FDA status notice above). See the full provider directory for complete profiles.

Trade-offs to know

BPC-157 carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved, cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that names its pharmacy, explains its follow-up schedule and states the regulatory status of what it prescribes.

Related peptides in the recovery category

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

References

  1. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 26967018
  2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. PMID: 25415480
  3. Vukojević J, Siroglavić M, Kašnik K, et al. Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascul Pharmacol. 2018;106:54-66. PMID: 29501670

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.